Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADELA: Elacestrant + Everolimus vs Elacestrant in ESR1-mutated ER+/HER2- Advanced Breast Cancer
2024-512926-27-00Phase 3Authorised
- Sponsor
- MEDSIR
- Start
- Nov 2024
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Orserdu + everolimus with Orserdu + placebo (2 arms). Primary endpoint: Progression-free survival (PFS) by BIRC. Planned start Nov 2024; status: authorised.
02
Drugs
elacestranteverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512926-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512926-27-00.